Expert Opinion on Pharmacotherapy

Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments
pp. 1685-1699(15)
Authors: Barmoshe, Sas; Zlotta, Alexandre R

Lipid-lowering effects of statins: a comparative review
pp. 1701-1714(14)
Authors: Davidson, Michael H; Robinson, Jennifer G

Levodopa, motor fluctuations and dyskinesia in Parkinson's disease
pp. 1715-1730(16)
Authors: Müller, Thomas; Russ, Hermann

Emerging pharmacotherapeutic agents for insomnia: a hypnotic panacea?
pp. 1731-1738(8)
Authors: Navab, Pedram; Guilleminault, Christian

A review of atypical antipsychotic drugs versus conventional medication in schizophrenia
pp. 1739-1748(10)
Authors: Luft, Barrat; Taylor, David

Cost-effectiveness of atypical antipsychotic medications versus conventional medication
pp. 1749-1758(10)
Authors: Hanrahan, Patricia; Luchins, Daniel J; Fabian, Robert; Tolley, George

Defining the genetic aetiology of monogenic diabetes can improve treatment
pp. 1759-1767(9)
Authors: Gloyn, Anna L; Ellard, Sian

InforMatrix^®: treatment of rheumatoid arthritis using biologicals
pp. 1769-1789(21)
Authors: van den Bemt, Bart JF; van den Hoogen, Frank HJ; Breedveld, Ferdinand C; van der Tempel, Hille; Janknegt, Rob

Nelarabine in the treatment of refractory T-cell malignant diseases
pp. 1791-1799(9)
Authors: Kline, Justin; Larson, Richard A

Sildenafil for pulmonary arterial hypertension: when blue turns into white
pp. 1801-1810(10)
Author: Antoniu, Sabina A

Once-daily tramadol in rheumatological pain
pp. 1811-1823(13)
Authors: Mattia, Consalvo; Coluzzi, Flaminia

Sertindole: efficacy and safety in schizophrenia
pp. 1825-1834(10)
Authors: Lindström, Eva; Levander, Sten

Lamivudine treatment in patients with chronic hepatitis B and cirrhosis
pp. 1835-1843(9)
Authors: Haché, Chantal; Villeneuve, Jean-Pierre